Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
Year: 2024
Type: article
Abstract: What is this summary about? This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug). The first results from the PRIMA study were published in 2019, when patients had participated in the PRIMA study for about 1.2 years. The article this PLSP is based on reports longer-term data from the PRIMA study, when patients had participated in the PRIMA study for about 3.5 years. Patients were monitored (or followed) for a longer time to understand how well niraparib continued to work and to evaluate whether the safety of niraparib changed with additional time being monitored. What were the results? Patients who took niraparib had more time before their cancer came back or got worse than patients who took placebo. In terms of safety, no new types of side effects with niraparib treatment were observed with additional time being monitored as part of the PRIMA study. What do the results mean? These results support that niraparib remains an important treatment option to help delay the cancer from coming back or getting worse in patients with newly diagnosed advanced ovarian cancer that responded to initial treatment. Clinical Trial Registration: NCT02655016 (PRIMA study) (ClinicalTrials.gov)
Source: Future Oncology
Authors: Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Izabela A Malinowska, Luda Shtessel, Natalie Compton, Mansoor R Mirza, Bradley J Monk
Institutions: Clinica Universidad de Navarra, Spanish Ovarian Cancer Research Group, Centro de Investigación Médica Aplicada, Gynecologic Oncology Group, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Universitair Ziekenhuis Leuven, Medical University of South Carolina, Humanitas University, Agostino Gemelli University Polyclinic, Université de Lyon, Hospices Civils de Lyon, The Ohio State University, Humboldt-Universität zu Berlin, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, Kliniken Essen-Mitte, Charité – Universitätsmedizin Berlin, Hospital Universitario La Paz, University of Rochester Medicine, University of Rochester, University of Antwerp, AZ Maria Middelares, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Copenhagen University Hospital, Rigshospitalet, Nordic Society of Gynecologic Oncology, Florida Cancer Specialists & Research Institute, University of Arizona College of Medicine- Phoenix
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4392960498